Pakistan Pharma Exports Slump 25 Percent as Afghan Trade Halt Bites

💊 After contracting by 30.26 percent in FY26, Pakistan's pharmaceutical exports continued to decline in the new fiscal year, falling 25.53 percent in value in the first quarter of 2026-27 — and the industry largely attributes the drop to disrupted trade with Afghanistan, once one of the country's main medicine markets. The numbers tell of an export industry that has lost its anchor customer almost overnight.

📊 Pakistan Bureau of Statistics data showed pharmaceutical exports fell to $319.012 million in FY26 from $457.456 million in FY25 — a drop of $138.444 million — while export volumes declined 26.14 percent to 83,104 tonnes from 112,517 tonnes. The pressure carried into the first quarter of FY27, with proceeds falling 25.53 percent to $73.301 million from $98.428 million a year earlier, and volumes falling a steeper 31.40 percent, from 23,924 tonnes to 16,410 tonnes. Average export value per tonne rose about 8.6 percent in the first quarter, from around $4,115 to $4,469, but fell 5.6 percent in FY26 — averages that reflect changes in the mix of products exported rather than necessarily in medicine prices.

🧪 The scale of the Afghan dependence is the story's core. Data on the TDAP Pakistan Pharma Portal, sourced from PRAL, showed Pakistan exported $155.68 million worth of medicines to Afghanistan in FY25 — about 34.1 percent of the country's total pharmaceutical exports that year. Losing a market of that share in a border economy bound to Pakistan by geography, language and treatment pathways is a structural shock, not a cyclical dip; land routes that moved affordable generics to Afghan hospitals and pharmacies do not re-route easily around a closed frontier.

🏥 Former Pakistan Pharmaceutical Manufacturers Association (PPMA) Chairman Tauqeer ul Haq said the suspension of trade with Afghanistan had caused heavy losses for pharmaceutical companies and the national exchequer — and stressed that Afghan patients were also suffering, as they had to turn to more expensive medicines. He said the PPMA had raised the issue with the government and Planning Minister Ahsan Iqbal had promised to discuss it with the relevant authorities and look for ways to restart Pakistani medicine exports, but there had been little serious follow-up.

🗳 One bright spot sits outside these figures: exports of surgical goods and medical instruments, which are not included in the pharmaceutical numbers, rose 8.8 percent to $121 million in the first quarter of FY27 and held steady at $451.527 million for FY26 — a reminder that the country's medical trade distress is concentrated in finished medicines rather than across the whole health-products complex.

🌏 The regional read: supply gaps get filled

🔎 For the wider South Asian pharmaceutical map, the lesson is that medicine supply chains abhor a vacuum. Afghan importers and health agencies must keep shelves stocked and treatment regimens running; where Pakistani routes close, purchases shift toward Indian products arriving through other channels, Iranian supplies entering from the west, and Chinese suppliers willing to ship — each of which takes share that is hard to win back once procurement relationships are rebuilt elsewhere. Trade suspensions, in other words, do not merely pause commerce; they redistribute it, and the pharmaceutical example shows how quickly a dominant supplier position built over decades can erode in the space of two fiscal years.

🚀 For Bangladesh's pharmaceutical industry — among the region's most capable, self-sufficient producers and a growing exporter in its own right — the episode is a case study in both risk and opportunity. The risk: dependence on a single neighbouring market concentrates exactly this kind of political exposure, a caution that applies to any export sector reliant on one corridor. The opportunity: buyers across the region who once sourced from Pakistan are actively looking for dependable alternatives, and Bangladeshi firms with WHO-GMP-compliant plants, competitive formulation costs and established aid-supply credentials are credible candidates — provided the trade diplomacy and logistics connections exist to serve markets at distance.

🔭 The human dimension deserves the final word, because it is the one both governments invoke and neither has solved: Afghan patients who relied on affordable Pakistani generics now pay more, take less or go without. Medical trade across a contested border is not an ordinary commercial question; its resumption requires the same customs corridors, security arrangements and banking channels as any goods trade — but with patients, not merely profits, waiting at the other end. Until Islamabad and Kabul rebuild those channels, the decline documented in these statistics will keep repricing itself in both currencies and in outcomes.

📡 The data trail also shows what competent crisis monitoring looks like, and its absence. The Pakistan Pharma Portal figures — product-level, destination-level, updated quarterly — gave analysts early, unambiguous warning of the collapse; what was missing was the policy response that should have followed. Pakistan's planning ministry received the industry's case, promised engagement, and produced, in the words of the former PPMA chairman, little serious follow-up — a sequence any trade-dependent economy should study. Export intelligence only matters if it triggers diplomacy, logistics negotiation and market diversification while the damage is still reversible; after two fiscal years of decline, the conversation in Islamabad has moved from mitigation to reconstruction.